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ABSTRACT
Objective: Platinum agents (PAs) are the most commonly used chemotherapeutic agents, aiming to induce tumor cell death by cytotoxicity. This 
leads to have high potential for toxicity and adverse effects. The main objectives of this study were to describe the incidence of side effects caused by 
platinum therapy and to conclude the management of treatment-related side effects for patients receiving platinum therapy.
Methods: A descriptive, retrospective study was carried out over a period of 9 months. Laboratory reports of 100 cancer patients were recorded. All 
statistical analyses were performed using SPSS 17.0 and GraphPad Prism. A p<0.05 (95% confidence interval) was considered significantly throughout 
the study.
Results: Among 100 patients 55% were male and 45% were female. A total of 70% (n=70) patients who received platinum compounds as 
chemotherapy regimen, among them 97.14% (n=68) patients appears to have anemia. Among the occurrence of adverse drug reactions, the incidence 
of anemia was found to be significant (n=68, 97.14%). Statistically significant difference was found in the incidence of anemia between PAs and non-
PAs treated group (p=0.0001).
Conclusion: Among PAs cisplatin-induced anemia and nephrotoxicity appears to be high in this study. There is a need to improve the management of 
anemia induced by PAs. Since anemia is preventable, this study emphasizes the need to improve the management of anemia induced by PAs.
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INTRODUCTION
The platinum derivatives such as cisplatin, carboplatin, and oxaliplatin 
are antineoplastic agents with remarkably useful in the treatment 
of several tumor types. Recognition of cisplatin’s cytotoxic activity 
was the result of a serendipitous observation that bacterial growth 
in culture was altered when an electric current was delivered to the 
media through platinum electrodes. The growth, change was noted 
to be similar to that produced by alkylating agents and radiation. It 
was found that a platinum chloride complex, now known as cisplatin, 
generated by the current was responsible for the changes. Carboplatin 
is structurally similar to cisplatin in which the chloride groups of the 
parent compound are replaced by a carboxycyclobutane moiety. It 
shares a similar spectrum of clinical activity with cisplatin, and cross 
resistance is common. Oxaliplatin is an organoplatinum compound in 
which the platinum is complexed with an oxalate ligand as the leaving 
group and to diaminocyclohexane. Its spectrum of activity differs 
substantially from the other platinum compounds and includes notable 
activity against colorectal cancers [1,2].
Platinum compounds are used for the treatment of testicular cancer, 
ovarian cancer, bladder cancer, head and neck cancer, esophageal 
cancer, small and non-small cell lung cancer, breast cancer, cervical 
cancer, stomach and prostate cancers, as well as Hodgkin’s and non-
Hodgkin’s lymphomas, neuroblastoma, sarcomas, multiple myeloma, 
and melanoma [3]. The cytotoxicity of the platinum derivatives 
depends on platinum binding to DNA and the formation of intrastrand 
cross-links or adducts between neighboring guanines which lead 
to cellular damage by distorting the normal DNA conformation and 
preventing bases that are normally paired from lining up with each 
other. Interstrand cross-links also occur [4].
Platinum agents (PAs) leads to diverse side-effects and toxicities 
due to cytotoxicity or apoptosis induced in cancer cells. The general 
toxicity profile differs between the three platinum drugs [5]. Cisplatin 
is an antineoplastic agent, with high potential for producing serious 
toxicities such as nephrotoxicity, ototoxicity, and peripheral neuropathy. 
Carboplatin is potential to cause renal damage, peripheral neuropathy, 
ototoxicity, nausea, and vomiting are much less than that of comparable 
cisplatin doses. Oxaliplatin produces peripheral neuropathies and 
unique cold-induced neuropathies [1,2,6]. All of the platinum derivatives 
have significant potential to cause hypersensitivity reactions, including 
anaphylaxis [7,8].
This current retrospective study was aimed to determine the incidence 
of treatment-related side effects in patients receiving platinum therapy 
and compare the effectiveness of existing management modalities in an 
outpatient oncology clinic.
METHODS
This retrospective observational study was carried out in an oncology 
department for 9 months from August 2015 to April 2016. The study 
protocol was approved by the Institutional Ethics Committee – IEC/
DOPV/2015/03 of Vels University. Consent from the hospital authorities 
and oncologists were obtained before accessing patient medical 
records. Biochemical parameters of cancer patients were recorded 
from the laboratory database.
Inclusion criterion
All cancer patients belonging to either gender or more than 18 years 
of age, who were receiving platinum compounds under any standard 
regimen, were included in the study.
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Exclusion criterion
Patients with documented pre-existing kidney disease, neurological 
disorder, history of allergic reactions to cisplatin or other platinum-
containing compounds, hearing impairment, and myelosuppression 
were excluded from the study.
Statistical analysis
The incidence of dichotomous categorical variables was analyzed 
by means of chi-square test to determine the presence or absence 
of statistically significant difference. All statistical analyses were 
performed using SPSS 17.0 and GraphPad Prism. A p<0.05 (95% 
confidence interval) was considered significantly throughout the 
study.
RESULTS
Among 100 patients 55% were male, and 45% were female. The various 
indications were cervical cancer, ovarian cancer, testicular cancer, 
lung cancer, stomach cancer, esophageal cancer, breast cancer, and 
squamous cell carcinoma. The most common indication was carcinoma 
cervix (Table 1).
The majority of patients were in the age group of 50-59 years (n=32), 
32% of patients was more prone to cancer, followed by 40-49 years 
(n=24, 24%) (Table 2).
The study population includes 100 cancer patients. Among them, 
70 (70%) patients were treated with platinum therapy, and 30 (30%) 
were treated with non-platinum therapy (Table 3).
The most common PAs used in this study population were cisplatin 
30 (30%), carboplatin 25 (25%), and oxaliplatin 15 (15%) (Table 4).
Side effects in cancer patient after platinum therapy were found to 
be fatigue 20 (28.5%), insomnia 7 (10%), dysphagia 10 (14.2%), 
itching and redness 8 (11.4%), bleeding 4 (5.7), constipation 2 (2.8%), 
numbness (10%), and vomiting 12 (17.14%) (Table 5 and Fig. 1).
The occurrence of anemia was found to be high with cisplatin treatment 
when compared with other PAs (Table 6 and Fig. 2).
A total of 70% (n=70) patients who received platinum compounds as 
chemotherapy regimen, among them 97.14% (n=68) patients appears 
to have anemia.
The incidence of anemia was compared between patients on PAs 
and non-PAs (NPA) using Chi-square test at 95% CI, and the result is 
graphically represented in Fig. 3.
The incidence of nephrotoxicity between PAs and NPAs was determined 
in cancer patients included in the study. The results are graphically 
represented in Fig. 4.
Table 1: Gender distribution
Gender Number of patients n=100 (%)
Male 55 (55)
Female 45 (45)
Table 2: Age distribution







Table 3: Platinum versus non‑platinum therapy
Therapy Number of patients n=100 (%) 
Platinum therapy 70 (70)
Non-platinum therapy 30 (30)
Table 4: PAs





Fig. 1: Side effects after platinum therapy in cancer patients
Fig. 2: Occurrence of adverse drug reactions after platinum 
therapy
Fig. 3: Incidence of anemia between platinum agents (PA) and 
non‑PAs treated groups (p=0.0001, odds ratio=136.0, relative 
risk=4. 857)
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DISCUSSION
The occurrence of toxicities in patients with cancer chemotherapy is 
found to be grave concern, the elimination of side effects, and possible 
toxicities become a major problem during chemotherapy, especially 
with PAs.
During 9 months of this study, case reports of 100 patients were 
analyzed out of which 55 (55%) were male and 45 (45%) were female. 
Among them, the majority of cancer patients were in the age group of 
50-59 (n=32, 32%). Among 100 cancer patients, 70 (70%) were treated 
with PAs cisplatin 30 (30%), carboplatin 25 (25%), and oxaliplatin 
15 (15%).
In our study, the following side effects were found to be fatigue 
20 (28.5%), insomnia 7 (10%), dysphagia 10 (14.2%), itching and 
redness 8 (11.4%), bleeding 4 (5.7), constipation 2 (2.8%), numbness 
(10%), and vomiting 12 (17.14%). The incidence of vomiting was 
secondary to fatigue. These findings were contrasted to the study 
reported by Swathi et al., 2015 and Laura et al., 2013 [9,10].
Among the occurrence of adverse drug reactions (ADRs), the incidence 
of anemia was found to be significant (n=68, 97.14%). 97.14% patients 
experienced anemia in the PA-treated group, whereas the incidence 
of anemia in NPA-treated group was found to be 20%. Statistically 
significant difference was found in the incidence of anemia between 
PA and NPA-treated group (p=0.0001). The occurrence of anemia 
was found to be high with cisplatin treatment when compared with 
other PAs [9,11]. Epoetin theta is a safe and effective treatment for 
anemia due to platinum-based chemotherapy in patients with solid 
Table 5: Side effects after platinum therapy in cancer patients









Table 6: Occurrence of ADR after platinum therapy
ADR Cisplatin (n=30) Carboplatin (n=25) Oxaliplatin (n=15) Total number of patients (n=70)
Abnormal renal function test 14 10 8 32
Anemia 29 24 15 68
Thrombocytopenia 6 7 4 17
Neutropenia 11 10 4 25
Neurotoxicity - 2 2 4
Leukocytosis 6 10 5 21
ADR: Adverse drug reactions
tumors with a weekly starting dose of 20,000 IU. It is superior to blood 
transfusion [11].
Cisplatin induces nephrotoxicity characterized by acute and chronic 
renal insufficiency, renal magnesium wasting and electrolyte 
disturbances. 45.71% patients experienced nephrotoxicity in the PA-
treated group, whereas the incidence of nephrotoxicity in NPA-treated 
group was found to be 13.33%. A statistically significant difference was 
found in the incidence of nephrotoxicity between PA and NPA-treated 
group (p=0.0064) [3,12].
Although nephrotoxicity was observed in the study population 
(n=32, 45.71%), the occurrence appears to be less when compared 
with anemia in this study (n=68, 97.14%). Frequency and severity 
of nephrotoxicity induced by platinum-based chemotherapy may be 
reduced by slow intravenous electrolyte infusions and maintaining the 
hydration before, during and immediately after the administration of 
PAs, especially cisplatin [12].
The other common adverse effect is myelosuppression characterized 
by neutropenia (n=25, 35.17%) and thrombocytopenia (n=17, 
32.85%). The reporting of ADRs has become an important component 
of monitoring and evaluation activities performed in hospitals [13]. 
The results of this study highlight the importance of monitoring the 
incidence of side effects in patients on platinum chemotherapy. The 
early detection and prompt management of these ADRs can reduce its 
health-related and economic effects on the patients [14].
CONCLUSION
Platinum-based chemotherapy is associated with increased the 
prevalence of toxicities and adverse effects. Among PAs cisplatin-
induced anemia and nephrotoxicity appears to be high in this study. 
97.1% of cancer patients experienced anemia in the PA-treated group, 
and also 92.85% cancer patients under platinum-based chemotherapy 
are exposed to ADR. Carboplatin-induced myelosuppression was 
found to be neutropenia (35.71%), thrombocytopenia (32.85%), and 
leucopenia (45.71%). There is a need to improve the management of 
adverse effects. Since anemia is preventable, this study emphasizes the 
need to improve the management of anemia induced by PAs.
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